文献速递血栓与止血

儿童癌症相关静脉血栓栓塞症的抗凝治疗:EINSTEIN-Jr 亚组分析

Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr.
PubMed 文献 · Blood Adv · 2022-01-01

EINSTEIN-Jr 随机研究纳入 500 例儿童静脉血栓栓塞症(VTE)患者,其中 56 例(11.2%)合并癌症,分配至利伐沙班治疗组(n=40)或标准抗凝组(n=16)。治疗 3 个月内无复发性 VTE 或大出血,大多数患儿血栓负荷减轻,利伐沙班暴露量在成人暴露范围内。

要点

  • 56 例癌症相关 VTE 患儿中,利伐沙班组 40 例、标准抗凝组 16 例,中位合并用药 30 种。
  • 治疗 3 个月内无复发性 VTE 或大出血(95%CI 0.0%-6.4%)。
  • 26 例(46.4%)患儿共中断抗凝治疗 70 次,平均个体中断 5.8 天,恢复治疗剂量后未发生血栓或出血并发症。

核心结论

  • 利伐沙班和标准抗凝药在癌症相关 VTE 患儿中似乎安全有效,且大多数患儿血栓负荷减轻,包括抗凝治疗中断者。
  • 尽管存在显著的多种药物联用,利伐沙班暴露量仍在成人暴露范围内。

研究设计与样本

  • EINSTEIN-Jr 随机研究的亚组分析,共 56 例癌症相关 VTE 患儿,其中血液系统恶性肿瘤占 64.3%、实体恶性肿瘤占 35.7%。
  • 患儿分配至治疗剂量体重调整口服利伐沙班组(n=40)或标准抗凝组(肝素类联合或不联合维生素 K 拮抗剂,n=16)。
  • 基于稳态稀疏采血,采用群体药代动力学(PK)建模推导利伐沙班的 PK 参数。

主要发现

  • 56 例患儿中位合并用药 30 种。
  • 治疗 3 个月内无复发性 VTE 或大出血(95%CI 0.0%-6.4%)。
  • 3 个月重复影像学检查显示,52 例可评估患儿中 20 例(38.5%)完全再通、24 例(46.2%)部分再通。
  • 26 例(46.4%)患儿因血小板减少、侵入性操作或不良事件共中断抗凝治疗 70 次,平均个体中断 5.8 天;恢复治疗剂量后未发生血栓或出血并发症。
  • 利伐沙班暴露量在成人暴露范围内,且与无癌症相关 VTE 的 VTE 患儿相似。

临床怎么用

  • 作者认为利伐沙班和标准抗凝药在癌症相关 VTE 患儿中似乎安全有效,且与大多数患儿血栓负荷减轻相关,包括抗凝治疗中断者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anticoagulant treatment of pediatric cancer-associated venous thromboembolism (VTE) has not been prospectively evaluated. Management of anticoagulation for cancer-associated VTE is often challenged by drug interactions and treatment interruptions. A total of 56 of the 500 children (11.2%) with VTE who participated in the recent EINSTEIN-Jr randomized study had cancer (hematologic malignancy, 64.3%, solid malignant tumor, 35.7%). Children were allocated to either therapeutic-dose bodyweight-adjusted oral rivaroxaban (n=40) or standard anticoagulation with heparins, with or without vitamin K antagonists (n=16) and received a median of 30 concomitant medications. Based on sparse blood sampling at steady-state, pharmacokinetic (PK) parameters of rivaroxaban were derived using population PK modeling. During the 3 months of treatment, no recurrent VTE or major bleeding occurred (95% confidence interval, 0.0%-6.4%), and 3-month repeat imaging showed complete or partial vein recanalization in 20 and 24 of 52 evaluable children (38.5% and 46.2%, respectively). Anticoagulant treatment was interrupted 70 times in 26 (46.4%) children because of thrombocytopenia, invasive procedures, or adverse events, for a mean individual period of 5.8 days. Anticoagulant therapy was resumed in therapeutic doses and was not associated with thrombotic or bleeding complications. Rivaroxaban exposures were within the adult exposure range and similar to those observed in children with VTE who did not have cancer-associated VTE. Rivaroxaban and standard anticoagulants appeared safe and efficacious and were associated with reduced clot burden in most children with cancer-associated VTE, including those who had anticoagulant treatment interruptions. Rivaroxaban exposures were within the adult exposure range despite significant polypharmacy use. This trial was registered at www.clinicaltrials.gov as #NCT02234843.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Palumbo JS, Lensing AWA, Brandão LR, et al. Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr. Blood Adv. 2022. PMID: 36006613. doi:10.1182/bloodadvances.2022008160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。